1 billion CFU · vegan · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
Bifidobacterium bifidum BGN4 is a proprietary probiotic strain originally isolated from healthy infant feces. It is one of the most extensively studied bifidobacterial strains for immune education, allergy prevention and eczema protection in infants and children. BGN4 has demonstrated the ability to modulate Th1/Th2 immune balance, enhance intestinal barrier function and reduce allergen permeability — key mechanisms in allergic disease prevention.
BGN4 enhances intestinal barrier integrity by upregulating tight junction proteins (occludin, claudin, ZO-1), reducing intestinal permeability and allergen translocation. It modulates dendritic cell maturation and promotes regulatory T-cell (Treg) development, shifting the immune response toward tolerance rather than hypersensitivity. A 2009 RCT showed that BGN4 + B. longum BORI significantly reduced atopic dermatitis (eczema) incidence in high-risk infants by 58% over 6 months. BGN4 also demonstrates anti-inflammatory activity by reducing IL-4, IL-5 and IgE in allergic models.
Parents of high-risk infants (family history of allergy/eczema) seeking probiotic prevention. Adults with allergic tendencies, eczema or atopic conditions. Those with compromised intestinal barrier function. Individuals seeking immune education and tolerance support. People with IBD or inflammatory gut conditions (under medical supervision).
Individuals with severe immunosuppression. Those with central venous catheters. Premature infants (consult neonatologist). People with artificial heart valves. Side effects: Extremely well-tolerated with excellent safety profile. No adverse effects in infant RCTs. Mild GI adjustment in first week for adults. As with all probiotics, immunocompromised individuals should consult a physician.
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 19840300 (infant eczema prevention RCT), PMID 17218154 (IBD prevention in mouse model), PMID 27649150 (BGN4 review — immune modulation and safety), PMID 18436293 (tolerance and cow's milk allergy trial)
SacredBod's longer take on Bifidobacterium Bifidum BGN4 — context the structured blocks above don't capture.
Bifidobacterium bifidum BGN4 is a proprietary probiotic strain originally isolated from healthy infant feces. It is one of the most extensively studied bifidobacterial strains for immune education, allergy prevention and eczema protection in infants and children. BGN4 has demonstrated the ability to modulate Th1/Th2 immune balance, enhance intestinal barrier function and reduce allergen permeability — key mechanisms in allergic disease prevention.
BGN4 enhances intestinal barrier integrity by upregulating tight junction proteins (occludin, claudin, ZO-1), reducing intestinal permeability and allergen translocation. It modulates dendritic cell maturation and promotes regulatory T-cell (Treg) development, shifting the immune response toward tolerance rather than hypersensitivity. A 2009 RCT showed that BGN4 + B. longum BORI significantly reduced atopic dermatitis (eczema) incidence in high-risk infants by 58% over 6 months. BGN4 also demonstrates anti-inflammatory activity by reducing IL-4, IL-5 and IgE in allergic models.
Parents of high-risk infants (family history of allergy/eczema) seeking probiotic prevention. Adults with allergic tendencies, eczema or atopic conditions. Those with compromised intestinal barrier function. Individuals seeking immune education and tolerance support. People with IBD or inflammatory gut conditions (under medical supervision).
Typical dose: 1 billion CFU per day
Form: capsules (60 count)
Best time: morning
With food: with-food
Expected onset: 2–4 weeks for gut colonisation; 4–8 weeks for immune benefits; 6+ months for allergy prevention in infants
Cycling: No cycling required. Can be taken continuously.
Known side effects: Extremely well-tolerated with excellent safety profile. No adverse effects in infant RCTs. Mild GI adjustment in first week for adults. As with all probiotics, immunocompromised individuals should consult a physician.
Who should avoid: Individuals with severe immunosuppression. Those with central venous catheters. Premature infants (consult neonatologist). People with artificial heart valves.
Avoid combining with: Antibiotics (take 2 hours apart), Immunosuppressants, Live vaccines (theoretical — consult paediatrician for infants)
Bifidobacterium Bifidum BGN4 is available on Amazon India with varying brand quality. When selecting a probiotic, verify CFU count at expiry (not just at manufacture), strain specificity and refrigeration requirements. Indian brand preferences include Tata 1mg, ZEROHARM, Carbamide Forte, HealthKart, Jarrow Formulas, Now Foods, and Meibotan. Prices vary significantly; compare cost-per-CFU rather than capsule count alone.
Schedule status in India: Not a Schedule H drug; available as dietary supplement.
Key citations: PMID 19840300 (infant eczema prevention RCT), PMID 17218154 (IBD prevention in mouse model), PMID 27649150 (BGN4 review — immune modulation and safety), PMID 18436293 (tolerance and cow’s milk allergy trial)
Evidence grade: B — n=see study in infant eczema RCT; multiple safety and mechanism studies
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
